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PreviewsAllostery Trumps
Antibiotic Resistance
In this issue of Structure, Kohl and colleagues report
on the structure of an antibiotic resistance kinase in
complex with an inhibitor selected from an ankyrin
repeat library that binds the enzyme with high affinity
and reverses antibiotic resistance in vivo (Kohl et
al., 2005).
Kinases are ubiquitous modulators of protein function,
modifiers of small molecules and nucleic acids, key
catalysts in biotransformations, and essential compo-
nents in cellular networks that sense and respond to
external and internal stimuli. The superfamily of Ser/
Thr/Tyr kinases has in particular garnered tremendous
attention from the research community as a result of
their vital roles in cellular signal transduction. Here pro-
tein and the related lipid kinases play key switching
roles in cell death and mitogenesis, controlling the cell
cycle and associated phenomena. As a result, this su-
perfamily of enzymes figures prominently in associated
diseases of cell growth and regulation such as cancer.
Modulation of kinase activity therefore has been tar-
geted by members of the scientific community and the
pharmaceutical sector interested in identifying new
small-molecule anticancer agents.
Members of the protein kinase superfamily share
overall structural homology, with an N-terminal β sheet
domain and a C-terminal α-helical domain. All kinases
bind ATP with micromolar dissociation constants in a
structurally conserved deep binding pocket. The gen-
erally more shallow phosphate-accepting substrate
binding site, which is located primarily in the structur-
ally divergent C-terminal domain, is difficult to block
with nonpeptide inhibitors. As a consequence, the fo-
cus of most kinase-targeted drug discovery campaigns
has been on the ATP binding pocket, which is readily
amenable to small-molecule binding and for which am-
ple precedent is available. The challenge inherent in
this strategy is the ubiquity of cellular protein kinases
and the resultant off-target interactions of kinase inhibi-
tors. Approaches that identify new binding strategies
to inhibit kinases, both as in vivo tools to probe kinase
function and as drug leads, are therefore highly sought.
In this issue, Kohl et al. (2005) report the structure of
an inhibited kinase issuing from a new kinase inhibitor
binding strategy (Amstutz et al., 2005). The authors
have taken advantage of an antibiotic resistance ki-
nase, APH(3#)-IIIa, that phosphorylates aminoglycoside
antibiotics. This kinase shares structural homology with
protein kinases (Hon et al., 1997), has detectable pro-
tein kinase activity (Daigle et al., 1999), and can be in-
hibited by inhibitors of protein kinases that target the
ATP binding site (Daigle et al., 1997). The antibiotic re-
sistance phenotype conferred by APH(3#)-IIIa facilitates
inhibitor screening, and therefore this enzyme is gain-ing popularity as a model for research on protein kinase
screening and inhibition (e.g., Zhang et al., 2005).
The inhibitor of APH(3#)-IIIa identified by Kohl and
colleagues is an ankyrin repeat protein selected for
specific binding to the kinase. Ankyrin repeats are com-
mon elements incorporated into modular proteins that
participate in protein-protein interactions (Mosavi et al.,
2004). The ankyrin repeat element (AR) consists of a
helix-loop-helix motif connected to another repeat
through a variable loop or β-hairpin. This helix-loop-
helix-loop/β-hairpin motif forms the core element in the
AR structure, and a single protein can include anywhere
from 2 to over 30 tandem AR motifs. These AR domains
form extended surfaces suitable for protein-protein in-
teractions. As a result, the motif appears in a number
of biochemical contexts, including cell surface proteins
and regulatory proteins.
Plückthun and colleagues have developed the AR re-
peat for engineering of protein binding proteins (Binz et
al., 2004). Using a modular approach consisting of N- and
C-terminal caps sandwiching AR cassettes, they have
designed and constructed protein libraries that display
random amino acids on one surface of the protein (Figure
1A). These libraries are then used in ribosome-display se-
lection to identify AR binders of bait proteins. Using
APH(3#)-IIIa in this mode, the group identified several
members of a randomized library that bound to the ki-
nase with low dissociation constants (nM) and inhibited
the in vitro aminoglycoside antibiotic phosphorylation ac-
tivity (Amstutz et al., 2005). Furthermore, coexpression of
some of these AR inhibitors in E. coli expressing APH(3#)-
IIIa reversed the antibiotic resistance phenotype, thereby
demonstrating that these selected AR proteins have both
potent in vitro and in vivo activity. The mode of interaction
of these AR proteins with APH(3)-IIIa was, however, un-
known until now.
The report in this issue by Kohl et al. (2005) ad-
dresses the question of how AR inhibition of aminogly-
coside kinase occurs through determination of the
X-ray structure of APH(3#)-IIIa in complex with one of
the more potent AR proteins selected in the screen,
AR_3a. The costructure reveals that AR_3a binds to the
C-terminal helical aminoglycoside binding domain of
APH(3#)-IIIa. Remarkably, the AR protein does not bind
in a competitive fashion with antibiotic in the aminogly-
coside binding pocket, but rather to an orthogonal
region of the protein. This nonactive site interaction re-
sults in trapping of an inactive conformation of the en-
zyme. Binding of aminoglycoside substrates to APH(3#)-
IIIa is associated with movement of helices in the
C-terminal domain and formation of an obligate ionic
interaction between the antibiotic substrate and the
carboxylate of the C-terminal residue Phe264 (Thomp-
son et al., 1999). The interaction of APH(3#)-IIIa and AR_
3a results in a conformational change that distorts the
aminoglycoside binding pocket through movements of
key α helices, leading to conformation(s) of the C-ter-
minal domain that are unproductive for antibiotic bind-
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Figure 1. AK Repeat Libraries and Inhibition of APH(3#)-IIIa
(A) The AK repeat library consists of N- and C-terminal caps (in
Cyellow and green, respectively) and a series of AK modules (blue)
with a variable region (red) that presents on one side of the folded
protein.
S(B) Interaction of AR_3a with APH(3#)-IIIa (green) results in a confor-
mational change that alters the aminoglycoside binding site and
Aprevents productive binding of antibiotic for detoxification.
M
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ing (Figure 1B). This structural rearrangement also im- P
pacts the positioning of the free carboxylate of Phe264 5
such that it is no longer available to stabilize the antibi- D
otic in the binding pocket. The result of this interaction 2
is powerful inhibition of antibiotic kinase activity and D
Creversal of resistance in vivo.
HThis work mirrors the interactions of regulatory proteins
Dwith cognate protein kinases that are common in many
Keukaryotic cells to control kinase activity. The AR library
Gapproach demonstrates that this paradigm can be har-
t
nessed in the discovery of novel reagents to modulate
Mcellular enzyme activity, which complements other strate-
(
gies such as gene inactivation and RNAi. Furthermore,
T
this research demonstrates that novel inhibitory modal- A
ities with biological impact can be discovered using the Z
modular AR library approach coupled with structure de- C
2termination. In this specific example, a new inhibitor bind-ng mode has been uncovered for an important antibiotic
esistance enzyme. This type of interaction can now serve
s a model for the design of small-molecule inhibitors
hat inhibit APH(3#)-IIIa in a similar fashion, which could
ind clinical utility in blocking antibiotic resistance. Fur-
hermore, the affinity of the AR_3a inhibitor for the en-
yme also provides an opportunity to develop displace-
ent assays that could be used to discover these
olecules in a random screen. This general approach
hould be amenable to several enzyme classes, espe-
ially where a powerful biological readout (e.g., drug re-
istance in this case) can serve as primary screen.
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